Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Recruiting

Phase 1

Phase 2

ONC-392 & Anti-PD-1Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Sponsor:

OncoC4, Inc.

Code:

NCT04140526

Conditions

Non Small Cell Lung Cancer

Advanced Solid Tumor

Metastatic Melanoma

Metastatic Head and Neck Carcinoma

Metastatic Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ONC-392

Pembrolizumab

Docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-19. This information was provided to ClinicalTrials.gov by OncoC4, Inc. on 2025-02-03.